Handbook of Pharmaceutical Science and Technology Studies: (Research Handbooks in Science and Technology Studies series)

About the Book

This comprehensive Handbook examines innovation in the pharmaceutical sector using ideas drawn from the interdisciplinary field of science and technology studies (STS). Leading experts present diverse social science approaches to pharmaceuticals, consolidating existing research and providing an agenda for future research in this area.

International contributors critically analyse the global dynamics of knowledge production, the political economy of manufacturing, the making of markets, their regulation and governance, and the diverse ecologies of consumption for pharmaceuticals. The Handbook deconstructs the constituent parts that make up the social, political and economic power of the pharmaceutical sector while also foregrounding alternatives to the dominant mode of innovation and production.

The Handbook of Pharmaceutical Science and Technology Studies is an essential resource for students and scholars in STS, economics, innovation and technology, health and social policy. It is also a valuable read for policymakers, professionals and practitioners involved in global bio-pharma innovation.

Table of Contents:
Contents Introduction to the Handbook of Pharmaceutical Science and Technology Studies xviii Conor Douglas, Susi Geiger, Tineke Kleinhout-Vliek, Paul Martin and Sarah Wadmann PART I THE DEVELOPMENT OF PHARMACEUTICALS 1 The production of pharmaceutical knowledge 2 Paul Martin 2 Myths about innovation in the pharmaceutical industry 8 Joel Lexchin 3 From bench to bedside and back again 25 Joshua R. Moon 4 Population-making in the regulatory arenas of clinical trials 41 Jakob Wested 5 The dynamics of “Orphanization” and the move towards precision medicine 57 Paul Martin, Andy Bartlett, Jin Ding, Matthew S. Hanchard and Eva Hilberg 6 How can innovation policy address “market failures” in the development of novel medicines? 70 Jin Ding, Michael M. Hopkins and Jorge Mestre-Ferrandiz 7 Social pharmaceutical innovation (SPIN): A sensitizing concept for challenges in rare diseases 90 Conor M. W. Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Wouter Boon, Claudio Cordovil Oliveira, Ellen Moors, Shir Grunebaum and Fernando Aith PART II MANUFACTURING AND PRODUCTION OF PHARMACEUTICALS 8 Introduction to Part II: The political economy of the manufacturing and production of pharmaceuticals 111 Conor M. W. Douglas 9 Vaccine nationalism beyond COVID-19: Prior dynamics and subsequent effects 121 Vesna Trifunović, Jan Hendriks and Stuart Blume 10 Peripheral vaccine promises in Latin America: Expectations, coalitions, and sovereignty 138 Gabriela Bortz, María Cecilia Sanmartin and Elize Massard da Fonseca 11 A world of generics: The manufacturing and circulation of generic medicines worldwide 159 Etienne Nouguez 12 Manufacturing and production of advanced therapies: A case of blurred boundaries 172 Michael Morrison, Isabel Briz Hernandez and Conor M. W. Douglas 13 Between activism and entrepreneurship: Challenging epistemic authority through pharmaceutical peer production 190 Bianca Jansky, Shane O’Donnell, Henriette Langstrup and Muireann Quigley 14 Drugged ecologies: The case of pharmaceutical pollution 204 Gergely Mohácsi PART III PHARMACEUTICAL MARKETIZATION: HOW MARKETS IN PHARMA ARE MADE AND SHAPED 15 Pharmaceutical marketization: How markets in pharma are made and shaped 223 Susi Geiger 16 The financialization of the pharmaceutical industry: the case of Novo Nordisk’s Wegovy 232 Prof Joan Busfield 17 “The price that we pay is not the real price of the medicine”: How the pharmaceutical price architecture facilitates financial accumulation 249 Susi Geiger and Théo Bourgeron 18 Medical writing, the marketing playbook, and the pharmaceutical industry 264 Maud Bernisson, Willem Halffman and Sergio Sismondo 19 The work digital does in pharmaceutical markets 281 Gemma Milne and Mathias Møllebæk 20 Pharmaceuticals from and for the Global South 298 Jean-Paul Gaudillière and Fanny Chabrol PART IV REGULATION AND GOVERNANCE OF PHARMACEUTICALS 21 “Regimes of pharmaceutical governance” 315 Tineke Kleinhout-Vliek 22 Expedited pathways in drug regulation: Evidence, uncertainty, and acceleration in biomedical innovation 324 Mathias Møllebæk 23 From unmet medical needs to dilemmas of access to treatment: the case of rare diseases and orphan drugs 337 Carlos Novas 24 The (ill)logics of patient engagement in drug development and evaluation 349 Olga Zvonareva and Hadewych Honné 25 Preventing, detecting, and responding to falsified and substandard medicines 372 Raffaella Ravinetto, Amalia Hasnida and Koen Peeters Grietens 26 Universal aspirations and contextual decisions: The Essential Medicines List and Health Technology Assessment 391 Tineke Kleinhout-Vliek and Susi Geiger PART V USE AND MISUSE OF PHARMACEUTICALS 27 Ecologies of pharmaceutical consumption 408 Sarah Wadmann 28 De/prescribing matters: Ecologies of prescribing and deprescribing in Science and Technology Studies 419 Lisa Lehner, Honja Hama, Igor Grabovac and Janina Kehr 29 Ecologies of resistance: The biosocial worlds of antibiotics 442 Joyce Sauann Lu and Omar Dewachi 30 Precision medicine and the reconfiguration of clinical practice and patienthood 462 Sarah Wadmann, Amalie Martinus Hauge, Anna Brueckner Johansen and Laura Emdal Navne 31 Beyond lay pharmacology: Fugitive, alternative, and pluralistic pharmacologies as collective practice 482 Magdalena Góralska, Anthony Rizk and Nayantara Sheoran Appleton 32 Pharmaceutical leakage: The porous interplay between legal and illegal opioid markets 497 Anne M. Lovell and Nancy D. Campbell 33 The food challenge to pharma: the unexplored potential of food drugs 512 Stephanie A. Nairn PART VI AFTERWORD 34 Reflections: Pharmaceuticals and biotechnologies through STS lenses 529 Sergio Sismondo

About the Author :
Edited by Conor M.W. Douglas, Associate Professor, Department of Science, Technology and Society, York University, Canada, Susi Geiger, Professor of Markets, Organisations and Society, School of Business, University College Dublin, Tineke Kleinhout-Vliek, Researcher in Pharmaceutical Market Contestation, School of Business, University College Dublin, Ireland, Paul Martin, Professor, School of Sociological Studies, Politics and International Relations, University of Sheffield, UK and Sarah Wadmann, Senior Researcher, VIVE - Danish Center for Social Science Research, Denmark